Health
Gout medication reduces major cardiovascular events in heart patients – News-Medical.Net
Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease, according to results of the LoDoCo2 trial presented in a Hot Line session today at ESC Congress 2020.
Reviewed by Emily Henderson, B.Sc.Aug 31 2020
Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease, according to results of the LoDoCo2 trial presented in a Hot Line session today at ESC Congress 2020.
Over a decade, more than one in three heart patients will have another heart attack or stroke, or die from heart disease, despite taking preventive medication. Our study shows that this could be reduced to one in four with the addition of low-dose …
-
General12 hours agoBritish and US planes fly 12-hour mission to patrol Russian border
-
Noosa News15 hours agoWarm weather could make way for rain with ‘damaging winds, large hail’
-
Noosa News21 hours agoBrisbane muralist explains why he ended his plan to eat one chicken a day for a year
-
General14 hours agoYoung boy flown to Brisbane hospital after K’gari dingo attack